Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Conditions
Brief summary
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle (Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with metastatic breast cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can prevent cancer growth by blocking the ability of cancer cells to grow and spread. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial evaluates a maintenance treatment with erlotinib and bevacizumab after Nab-paclitaxel and bevacizumab which may control cancer growth with biologic therapies.
Detailed description
PRIMARY OBJECTIVES: I. Progression free survival. SECONDARY OBJECTIVES: I. Response rate. II. Overall survival. III. Safety and toxicity. IV. Exploratory biomarkers will be assessed as potential predictors of response to treatment including: expression of epidermal growth factor receptor (EGFR) and secreted protein acidic and rich in cysteine (SPARC) in the primary tumor and changes in levels of circulating tumor cells (CTCs) and circulating endothelial cells (CECs). OUTLINE: INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV) on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride orally (PO) once daily (QD) in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up per physician discretion.
Interventions
DRUGpaclitaxel albumin-stabilized nanoparticle formulation
Given IV
BIOLOGICALbevacizumab
Given IV
DRUGerlotinib hydrochloride
Given PO
Sponsors
National Cancer Institute (NCI)
University of Washington
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* Have histologically confirmed invasive breast cancer that is estrogen receptor (ER) negative (=\< 10%), progesterone receptor (PR) negative (=\< 10%) and human epidermal growth factor receptor 2 (HER2) normal (=\< 10% of cells) by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) * Be receiving first-line therapy for metastatic disease * Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria; X-rays, scans or physical examinations used for tumor measurement must have been completed within 28 days prior to registration; X-rays, scans or other tests for assessment of non-measurable disease must have been performed within 42 days prior to registration * OR non-measurable disease only, with rising serum cancer antigen (CA)15-3 or CA 27.29 or carcinoembryonic antigen (CEA) documented by two consecutive measurements taken at least 14 days apart with the most recent measurement being within 42 days prior to registration; the second CA 15-3 or CA 27.29 or CEA value must have at least a 20% increase over the first and for CA 15-3 or CA 27.29 be greater than or equal to 40 units/mL or for CEA be greater than or equal to 4 ng/mL * Subjects with brain metastases as their first site of disease recurrence may be eligible if treated by definitive radiation (stereotactic radiosurgery or whole brain) with clinically controlled neurologic symptoms for a period of 21 days prior to study treatment * Bilirubin =\< 1.5 mg/dL * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis * Alkaline phosphatase =\< 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis * Platelets \> 100,000 cells/mm\^3 * Hemoglobin \> 9.0 g/dL * Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3 * Creatinine =\< 1.5 mg/dL is recommended; however, institutional norms are acceptable * If of childbearing potential must have a negative pregnancy test and use an effective method to avoid pregnancy for the duration of the trial and for at least 6 months after completion of study therapy * Pre-existing peripheral neuropathy, if present, must be \< grade 2 (per Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0) * Patients must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional standards and federal guidelines
Exclusion criteria
* Recurrent disease within 12 months after completion of adjuvant chemotherapy containing a weekly taxane * Central nervous system (CNS) metastases that are symptomatic and/or requiring steroids * Pre-existing nephritic syndrome * Serious intercurrent medical or psychiatric illness including serious active infection * Inadequately controlled hypertension (defined as systolic blood pressure \> 150 and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications) * Any prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) grade II or greater congestive heart failure * History of myocardial infarction or unstable angina within 6 months prior to study enrollment * History of stroke or transient ischemic attack within 6 months prior to study enrollment * Significant vascular disease (e.g., aortic aneurysm, aortic dissection) * Symptomatic peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment * Serious, non-healing wound, ulcer, or bone fracture * Proteinuria at screening as demonstrated by either: * Urine protein:creatinine (UPC) ratio \>= 1.0 at screening OR * Urine dipstick for proteinuria \> 2+ (patients discovered to have \> 2+ proteinuria on dipstick urinalysis at baseline must have a UPC ratio done that is \< 1.0 to be eligible; if the UPC ratio is \>= 1.0 then the patient should undergo a 24-hour urine collection which must demonstrate =\< 1 g of protein in 24 hours for the patient to be eligible) * Known hypersensitivity to any component of bevacizumab or to nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause, assessed up to 8 years | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Kaplan-Meier survival curves will be used. A 95% confidence interval for the median PFS will be calculated. A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is superior to paclitaxel and bevacizumab. However, a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median extends below 8 months) could also indicate promising results. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Response | Up to 8 years | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
| Incidence of Adverse Events as Assessed by National Cancer Institute CTCAE Version 3.0 | Up to 30 days after treatment discontinuation | Adverse events that meet severity grade 2 or greater will be collected and reported. The number and percent of subjects reporting adverse events (all, severe or worse, serious and related) will be summarized for all patients, and stratified by center and other subgroups of interest. |
| Overall Survival | Time from date of registration to date of death due to any cause, assessed up to 8 years | Kaplan-Meier survival curves will be used. |
| Changes in Levels of Circulating Tumor Cells | Baseline to up to 8 years | Descriptive statistics, such as mean, standard deviation, and range, will be summarized for circulating tumor cells at baseline and last visit. |
| Changes in Levels of Circulating Endothelial Cells | Baseline to up to 8 years | Descriptive statistics, such as mean and standard deviation, will be summarized for circulating endothelial cells at baseline and last visit. |
| EGFR and SPARC Expression in the Primary Tumor | Up to 8 years | — |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Tx (Chemo, MoAb, and Enzyme Inhibitor) INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity.
paclitaxel albumin-stabilized nanoparticle formulation: Given IV
bevacizumab: Given IV
erlotinib hydrochloride: Given PO | 55 |
| Total | 55 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 4 |
Baseline characteristics
| Characteristic | Tx (Chemo, MoAb, and Enzyme Inhibitor) |
|---|---|
| Age, Continuous | 55.3 years STANDARD_DEVIATION 12.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 6 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 47 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 47 Participants |
| Sex: Female, Male Female | 55 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 3 / 55 |
| other Total, other adverse events | 52 / 55 |
| serious Total, serious adverse events | 5 / 55 |
Outcome results
Primary
Progression-free Survival (PFS)
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Kaplan-Meier survival curves will be used. A 95% confidence interval for the median PFS will be calculated. A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is superior to paclitaxel and bevacizumab. However, a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median extends below 8 months) could also indicate promising results.
Time frame: Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause, assessed up to 8 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Tx (Chemo, MoAb, and Enzyme Inhibitor) | Progression-free Survival (PFS) | 9.1 Months |
Secondary
Changes in Levels of Circulating Endothelial Cells
Descriptive statistics, such as mean and standard deviation, will be summarized for circulating endothelial cells at baseline and last visit.
Time frame: Baseline to up to 8 years
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tx (Chemo, MoAb, and Enzyme Inhibitor) | Changes in Levels of Circulating Endothelial Cells | log10(CEC) at baseline | 1.458 log10 of CEC per mL | Standard Deviation 0.491 |
| Tx (Chemo, MoAb, and Enzyme Inhibitor) | Changes in Levels of Circulating Endothelial Cells | log10(CEC) at last visit | 1.332 log10 of CEC per mL | Standard Deviation 0.574 |
Secondary
Changes in Levels of Circulating Tumor Cells
Descriptive statistics, such as mean, standard deviation, and range, will be summarized for circulating tumor cells at baseline and last visit.
Time frame: Baseline to up to 8 years
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tx (Chemo, MoAb, and Enzyme Inhibitor) | Changes in Levels of Circulating Tumor Cells | log10(CTC) at baseline | 0.857 log10 of CTC per mL | Standard Deviation 0.854 |
| Tx (Chemo, MoAb, and Enzyme Inhibitor) | Changes in Levels of Circulating Tumor Cells | log10(CTC) at last visit | 0.531 log10 of CTC per mL | Standard Deviation 0.756 |
Secondary
EGFR and SPARC Expression in the Primary Tumor
Time frame: Up to 8 years
Population: Data published that shows that running assay does not provide useful results
Secondary
Incidence of Adverse Events as Assessed by National Cancer Institute CTCAE Version 3.0
Adverse events that meet severity grade 2 or greater will be collected and reported. The number and percent of subjects reporting adverse events (all, severe or worse, serious and related) will be summarized for all patients, and stratified by center and other subgroups of interest.
Time frame: Up to 30 days after treatment discontinuation
Population: Of the 59 patients enrolled, 4 patients failed to complete a single cycle of induction and considered invaluable and therefore were removed from efficacy analysis. Safety analysis included all 59 patients.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Tx (Chemo, MoAb, and Enzyme Inhibitor) | Incidence of Adverse Events as Assessed by National Cancer Institute CTCAE Version 3.0 | Grade 3, 4 Toxicities for Induction | 34 Participants |
| Tx (Chemo, MoAb, and Enzyme Inhibitor) | Incidence of Adverse Events as Assessed by National Cancer Institute CTCAE Version 3.0 | Grade 3, 4 Toxicities for Maintenance | 14 Participants |
Secondary
Overall Survival
Kaplan-Meier survival curves will be used.
Time frame: Time from date of registration to date of death due to any cause, assessed up to 8 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Tx (Chemo, MoAb, and Enzyme Inhibitor) | Overall Survival | 18.1 Months |
Secondary
Percentage of Participants With Response
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 8 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tx (Chemo, MoAb, and Enzyme Inhibitor) | Percentage of Participants With Response | Partial Response | 74 percentage of participants |
| Tx (Chemo, MoAb, and Enzyme Inhibitor) | Percentage of Participants With Response | Stable Disease | 19 percentage of participants |